Quantitatively Assess Allelic Imbalance in Cancer by Real-Time Comparative Quantitative (CO-) PCR
Tech ID: 18745 / UC Case 2007-575-0
Cancer is genetic disease which is originated due to multiple genetic alterations, including mutation or loss of tumor suppressor genes and amplification of oncogenes, and consequently alteration of gene expression profile which alters the phenotype of normal cells. It is composed with genetically heterogeneous cell subgroups and normal cells. Information on the degree of loss of tumor suppressor genes or amplification of oncogene genes cancer mass can play important role to prognosis of patient response to therapy, as well as survival.
This invention resolved all the drawbacks of past and current technologies and have incredible power on detection of allele imbalance of cancer genome. All loci are potentially informative, paired normal tissue is not required, gain can be distinguished from loss, and the data is independent of input quantify of sample DNA and standard DNA. Furthermore, it is a highly sensitive detection system, that the input DNA can be as little as 1 ng.
Real-time comparative quantitative PCR for test of allele imbalance in cancer.